Chronic Hepatitis C Clinical Trial
Official title:
Combination of Alpha Interferon With Long Term Ribavirin Therapy for Patients With Chronic Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of
the liver in approximately one-third of patients some of whom will ultimately suffer from
liver failure or liver cancer. At present, the recommended therapy of hepatitis C is the
combination of alpha interferon and ribavirin given for 6 to 12 months. Ribavirin is a
antiviral drug that is given by mouth. Interferon is both an antiviral and an immune
medication which must be given by injections (three times a week) and has many difficult
side effects. The purpose of this study is to determine whether the combination of ribavirin
and interferon improve the liver disease of hepatitis C and whether improvements can be
maintained by continuing ribavirin therapy long-term. This study will take 100 to 120
patients suffering from hepatitis C and place them under combination drug therapy with alpha
interferon and ribavirin. The course of drug therapy is scheduled to last 6 to 12 months.
Patients will be selected after appropriate screening for hepatitis C virus and elevated
liver enzymes are conducted and liver biopsy shows chronic hepatitis with some degree of
injury and scarring.
During the first 6 months of the study, subjects will be asked to return to the outpatient
clinic for routine check-ups and blood tests every 2 to 4 weeks. Blood tests will include
tests for hepatitis C virus. If the virus test becomes negative on treatment, the therapy
will be considered successful and will be continued for a full 6 or 12 months (depending
upon the strain of virus).
If the virus test does not become negative during the first six months of treatment,
subjects will be considered "non-responders" and will stop taking interferon but will
continue on ribavirin alone or an identically appearing placebo tablet. These non-responsive
subjects will continue this therapy for an additional 12 months. (A year-and-a-half total).
Upon completion of the drug therapies, subjects will be requested to submit blood samples
and undergo a liver biopsy to determine if the therapy was successful. Test results that
reveal a loss of hepatitis C antibodies or normal levels of liver enzymes will be deemed
successful.
Patients that have successful laboratory test results will be considered for continuation of
ribavirin therapy. Patients that received placebo for a year will be eligible to receive
ribavirin long-term at the end of the study.
Between 60 and 90 patients with chronic hepatitis C will be enrolled in a study of the
combination of alpha interferon and ribavirin for 12 months with early discontinuation of
therapy and randomization to receive either ribavirin alone or placebo for patients who do
not respond within 6 months of starting therapy. Adult patients will be chosen who have
chronic hepatitis C, HCV RNA in serum, and elevations in serum aminotransferases. Patients
who have received alpha interferon in the past will be eligible if they did not have a
sustained response to their previous course of interferon. After medical evaluation and
liver biopsy, patients will begin receiving alpha interferon by subcutaneous injection in a
dose of 3 million units three times weekly. At the same time, patients will begin receiving
ribavirin orally in a dose of 1000 mg (if body weight is less than 75 kg) or 1200 mg daily
(two or three capsules of 200 mg twice daily). During the initial 24-week period of
combination therapy, patients will be seen in the outpatient clinic for medical interview,
physical examinations and blood tests at 2 to 4 week intervals. At 24 weeks, patients will
be classified as either responders or non-responders based upon HCV RNA testing of serum.
Responders will continue on the combination therapy for another 24 weeks (total treatment =
48 weeks). Non-responders will stop interferon therapy and will be randomized to receive
either ribavirin or identically appearing placebo capsules for 48 weeks (total treatment =
72 weeks). At the 72 week point (18 months after enrollment), all patients will be
readmitted for repeat medical evaluation and liver biopsy. At this point, ribavirin and
placebo will be stopped (unless the patient has had a clear histological and biochemical
response to therapy) and patients will be monitored with outpatient visits at 8 week
intervals for another 6 months.
Patients who exhibit a histological and biochemical response to ribavirin monotherapy will
be offered a one-year extension of treatment with ribavirin in a gradually reduced dosage.
These patients will be monitored at 8 week intervals and the dose will be reduced by 200 mg
per day every 16 weeks to a minimum dose of 600 mg per day. If the biochemical response is
maintained, patients will continue on therapy for one year and then undergo repeat medical
evaluation and liver biopsy. Continued therapy with ribavirin after this point will depend
upon whether safety and efficacy of ribavirin have been demonstrated and whether ribavirin
has been approved for use in hepatitis C.
The primary criterion for success of therapy overall will be sustained loss of HCV RNA as
assessed at 18 months. Primary criteria for response among the patients who are randomized
to receive ribavirin or placebo will be degree of histological improvement on liver biopsy.
Secondary criteria will be normalization of ALT levels. This study will allow for therapy of
all patients with chronic hepatitis C with the combination of alpha interferon and ribavirin
and will allow for therapy of patients with resistant forms of chronic hepatitis C with
ribavirin alone and will address whether monotherapy with ribavirin can sustain these
improvements and whether the biochemical improvements reflect amelioration of the underlying
liver disease as judged histologically.
;
Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
Completed |
NCT03673696 -
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT02250001 -
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
|
N/A | |
Completed |
NCT03088917 -
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
|
||
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT02865369 -
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
|
N/A | |
Recruiting |
NCT02638233 -
Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy
|
Phase 4 | |
Not yet recruiting |
NCT02511496 -
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
|
N/A | |
Not yet recruiting |
NCT01949168 -
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
|
Phase 2 | |
Completed |
NCT02788682 -
Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy
|
N/A | |
Completed |
NCT01439776 -
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
|
Phase 4 | |
Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A | |
Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A | |
Terminated |
NCT00962936 -
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
|
Phase 1/Phase 2 | |
Completed |
NCT00968357 -
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
|
Phase 2 | |
Recruiting |
NCT01178749 -
Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments
|
N/A | |
Recruiting |
NCT00575627 -
Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
|
Phase 4 | |
Completed |
NCT00537407 -
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
|
Phase 2 | |
Recruiting |
NCT00370617 -
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance
|
Phase 4 | |
Completed |
NCT01684787 -
Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
|
Phase 4 |